(Source: American College of Cardiology Foundation) Cardiotoxicity is a well-recognized complication of chemotherapeutic agents. Cardiotoxicity encompasses multiple effects including subclinical injury, overt left ventricular (LV) dysfunction, and congestive heart failure (HF). The development of cardiotoxicity has important implications both during and subsequent to cancer therapy. Cardioprotective strategies include primary prevention and secondary prevention in those high-risk patients with subclinical cardiotoxicity. This review focuses on cardioprotective agents used in conjunction with cancer therapy. Radiation-induced heart disease and the treatment of cardiotoxicity are beyond the...
↧